Business UpdateJul 16, 2026, 07:41 AM
Virax Biolabs Secures Fosun Deal, $3.3M Funding, Regains Nasdaq Compliance
AI Summary
Virax Biolabs Group Ltd's CEO provided a shareholder update, highlighting the company's fiscal 2026 financial position with $6.4 million in cash and $7.3 million in shareholders' equity. The company announced a significant commercial supply agreement with Fosun Diagnostics for ImmuneSelect in six Southeast Asian markets and successfully raised $3.3 million through preferred investment options. Additionally, Virax Biolabs regained compliance with Nasdaq's minimum bid price requirement, strengthening its market position and liquidity.
Key Highlights
- Secured a multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets.
- Completed the exercise of preferred investment options, generating approximately $3.3 million in gross proceeds.
- Regained compliance with Nasdaq's minimum bid price requirement.
- Reported cash of $6.4 million, total assets of $8.3 million, and shareholders' equity of $7.3 million as of March 31, 2026.
- Net loss decreased to $5.0 million in fiscal 2026 from $6.1 million in fiscal 2025.
- Research and development expenses increased to $3.7 million in fiscal 2026 from $2.0 million.
- General and administrative expenses decreased to $2.7 million from $4.0 million.
Price Impact
More from VRAX